List of contributors, x
Preface, xii
Abbreviations, xiii

PART 1: GENERAL HEMOSTASIS

1 Schematic presentation of the hemostatic system, 3
   Nils Egberg

2 Proposals for sampling instructions, 6
   Margareta Blombäck and Nils Egberg
   Points to note prior to sampling, 6
   Sampling time and patient preparation, 7
   Referrals for coagulation analyses, 8
   Sampling, 8
   Technique, 9
   For DNA investigation (genetic analyses), 10

3 Laboratory investigations, 11
   Jovan P. Antovic, Liselotte Onelöv, and Nils Egberg
   Nomenclature, 11
   Reference intervals for laboratory investigations, 13
   Screening analyses, 13
   Special analyses, 20
   Markers of coagulation activation (hypercoagulation markers), 29
   DNA analyses, 29
   Global hemostatic assays and bedside methods, 31
   Useful components in research studies, 32
   Platelet-activating predictors, 35
PART 2: BLEEDING DISORDERS

4 Hereditary bleeding disorders, 41
   Margareta Holmström and Lars Göran Lundberg
   General remarks about hemophilia A and B, 41
   General remarks about von Willebrand disease, 42
   Factor concentrates used for treatment of hemophilia A and B and VWD in Sweden in 2012, 43
   Treatment strategy in severe forms of hemophilia and VWD, 44
   Recommendations for desired initial plasma concentrations at different types of bleedings, 45
   Surgery in patients with bleeding disorders, 47
   Tooth extraction in a hemophilia patient, 47
   Caution in patients with bleeding disorders, 48
   Treatment principles for different types of bleeding disorders (severe, moderate, and milder forms of hemostatic defects), 49
   Rare bleeding disorders, 51
   Blood sampling in bleeding disorders, 54
   Bleeding risk charts, 54

5 Critical bleeding, 56
   Maria Bruzelius, Anna Ågren, and Hans Johnsson
   Introduction, 56
   Definition of massive bleeding, 56
   Transfusion coagulopathy, 56
   Recommendations to obtain optimal hemostasis, 57
   Choice of plasma, 58
   Local procedures, 59
   Additional treatment, 59
   Fibrinogen concentrate, 59
   Prothrombin-complex concentrate (PCC), 59
   Recombinant factor VIIa, 59
   Concentrates of other coagulation factors, 60
   Cryoprecipitates, 60
   Tranexamic acid, 60
   Desmopressin, 60
   Local hemostatic drugs, 60
   Complicating factors, 61
   Ongoing treatment with antiplatelet, and anticoagulant drugs, 61
6 Investigation of increased bleeding tendency, 62  
Margareta Holmström and Lars Göran Lundberg

Introduction, 62
Diagnosis, 62
Reasons for pathologic screening analyses and further actions, 64
Causes of thrombocytopenia, 64
Causes of prolonged activated partial thromboplastin time, 65
Causes of elevated PT(INR), 66
Investigation of bleeding tendency: practical aspects, 66

PART 3: THROMBOEMBOLIC DISORDERS

7 Venous thrombosis and pulmonary embolism, 71  
Anders Carlsson

Introduction, 71
Venous thrombosis, 72
Pulmonary embolism, 75
Primary prophylaxis against VTE, 91

8 Investigations of thromboembolic tendency, 94  
Margareta Holmström

Introduction, 94
Venous thromboembolism, 95
Arterial thromboembolism, 96
Disseminated intravascular coagulation, 96

9 Heart disease, 97  
Håkan Wallen and Rickard Linder

Ischemic heart disease, 97
Atrial fibrillation, 102
Cardiac valve prosthesis, 103
New oral anticoagulants in the treatment of heart disease, 104

10 Antiplatelet drug therapy and reversal of its effects, 105  
Håkan Wallen, Hans Johnsson, and Bo-Michael Bellander

Introduction, 105
ASA, 105
ADP (P₂Y₁₂) receptor antagonists, 106
GPIIb/IIIa receptor antagonists, 106
Phosphodiesterase inhibitors and other antiplatelet compounds, 108
Contents

11 New oral anticoagulants: Focus on currently approved oral factor Xa and Thrombin inhibitors, 111
   Rickard E. Malmström and Hans Johnsson
   Clinical pharmacology of NOACs, 111
   Possibility of and need for therapeutic monitoring of NOACs, 114
   Clinical aspects of NOACs, 114
   Results of clinical trials, 116
   Some characteristics of the individual NOACs, 118
   Considerations to be taken when using NOACs in some emergency situations

12 Stroke and transient ischemic attack, 121
   Nils Wahlgren and Mia von Euler
   Antithrombotic secondary stroke prevention, 121
   Atrial fibrillation and TIA or stroke, 122
   Thrombolysis in stroke, 122
   Cerebral venous thrombosis and dissection of precerebral arteries, 123
   Recurrent TIA, 124
   Prophylactic treatment against DVT and PE, 124

13 Peripheral artery surgery, 125
   Jesper Swedenborg
   Prophylaxis against reocclusion in peripheral vascular surgery or percutaneous transluminal angioplasty (PTA), 125
   Peri- and postoperative treatment, 125
   Thrombolysis in acute ischemia, 126

PART 4: SPECIAL HEMOSTASIS

14 Hemostasis in obstetrics and gynecology, 129
   Katarina Bremme
   Introduction, 129
   Thrombosis during pregnancy, 131
   Heart disease: treatment of women with mechanical heart valve prostheses, 139
Thromboprophylaxis in obstetrics and gynecology, 140
Blood sampling in children of women with severe forms of thrombophilia, 148
Obstetric epidural/spinal analgesia (anesthesia), 148
Complications during pregnancy, 150
Postpartum bleeding, 155
Thromboprophylaxis in legal and spontaneous abortions, 156
Thromboprophylaxis in gynecologic surgery, 156
Investigation prior to artificial insemination (IVF), 160
Investigation in repeated miscarriages, 160
Investigation in menorrhagia (for treatment see Chapter 4), 161

15 Hemostasis in children, 162
Susanna Ranta and Pia Petrini
Introduction, 162
Bleeding disorders in children, 166
Thromboembolic disorders in children, 172

16 Emergency conditions associated with coagulation: DIC, HIT and TTP/HUS, 182
Jovan P. Antovic and Margareta Holmström
Disseminated intravascular coagulation, 182
Heparin-induced thrombocytopenia, 188
Thrombotic microangiopathies, 190

Index, 191